Core Viewpoint - Lingke Pharmaceutical is preparing for an IPO on the Hong Kong Stock Exchange, aiming to capitalize on the current trend of innovative drug companies performing well in the market [2][3]. Company Overview - Founded in 2017 in Hangzhou, Lingke Pharmaceutical specializes in innovative small molecule inhibitors for autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3]. - The company has two core products: LNK01001, a second-generation JAK1 inhibitor, and LNK01004, a third-generation pan-JAK inhibitor, both targeting autoimmune and inflammatory diseases [3][4]. Product Pipeline - LNK01001 is currently in Phase III clinical trials for atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis, with new drug applications expected to be submitted starting in 2026 [3]. - LNK01004 has completed Phase II trials for atopic dermatitis and plans to initiate Phase III trials in mid-2027 [3]. - LNK01006 is a TYK2 inhibitor targeting central nervous system diseases, with FDA approval for new drug clinical trials [4][6]. Financial Performance - Lingke Pharmaceutical has not yet generated product sales revenue, recording other income of RMB 20.57 million, RMB 16.98 million, and RMB 54.78 million for the first three quarters of 2023, 2024, and 2025, respectively [8][10]. - The company reported significant losses of RMB 260 million, RMB 312 million, and RMB 145 million for the same periods [10]. - R&D expenses were RMB 186 million, RMB 223 million, and RMB 121 million for the first three quarters of 2023, 2024, and 2025, respectively [8][10]. Funding and Cash Flow - Lingke Pharmaceutical has undergone multiple rounds of financing, attracting investments from various capital firms [7]. - The company has a high dependency on external financing, with net cash outflows from operating activities of RMB 228 million, RMB 241 million, and RMB 86 million for the first three quarters of 2023, 2024, and 2025 [12][13]. - As of September 30, 2025, the company held cash and cash equivalents of RMB 147 million, indicating a need for substantial funding to support R&D and commercialization efforts [14]. Use of IPO Proceeds - If the IPO is successful, Lingke Pharmaceutical plans to allocate funds towards the development of core products LNK01001, LNK01004, and LNK01006, enhancing R&D capabilities, upgrading office facilities, and general corporate purposes [14].

Company Overview - Lingke Pharmaceutical has submitted its IPO application to the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - Founded in November 2017 in Hangzhou by former executives from Pfizer, Merck, and Johnson & Johnson, the company focuses on the development of small molecule targeted innovative drugs for diseases such as cancer, immunity, and inflammation [1][2] - The company’s core products are in the clinical key stage, but financial data indicates significant pressure [1] Product Pipeline - The core competitiveness of Lingke Pharmaceutical lies in two main areas: JAK-STAT signaling pathway drugs and protein degradation technology [2] - The lead product, LNK01001, is a highly selective second-generation JAK1 inhibitor, currently undergoing three Phase III clinical trials for atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis, with new drug applications planned for 2026 and 2027 [2][3] - Another key product, LNK01004, is a potential first-in-class third-generation pan-JAK inhibitor, which has shown promising results in Phase II trials for atopic dermatitis [2][3] Research and Development - Lingke Pharmaceutical plans to initiate Phase II clinical trials for chronic hand eczema and vitiligo in China in 2026, and advance Phase III trials for atopic dermatitis in 2027 [3] - The company’s IsoNova protein degradation platform significantly enhances target selectivity and reduces off-target risks, shortening the R&D cycle from 18-24 months to just a few months for some candidates [3] - The R&D team consists of 57 members, with a strong focus on new drug exploration and clinical development, holding 53 issued patents and 106 pending patent applications [3] Financial Performance - Lingke Pharmaceutical has reported net losses of 260 million yuan and 312 million yuan for 2023 and 2024, respectively, with a loss of 145 million yuan in the first three quarters of 2025 [4] - The company’s cash flow from operating activities was negative, with net cash flows of -228 million yuan and -241 million yuan for 2023 and 2024, improving to -85.67 million yuan in 2025 [4][5] - The company primarily relies on equity financing for operations and has established a commercial partnership with Xiansheng Pharmaceutical for the commercialization of LNK01001 [5] Market Landscape - The global JAK inhibitor market is highly competitive, projected to grow from 13.9 billion USD in 2024 to 40.8 billion USD by 2033, with the Chinese market expected to increase from 3.8 billion yuan in 2024 to 46.5 billion yuan by 2033 [6] - Major multinational pharmaceutical companies like Pfizer and AbbVie have established a competitive advantage, while several domestic companies are also in Phase III clinical trials for their JAK inhibitors [6]

Core Viewpoint - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative small molecule inhibitors for autoimmune and inflammatory diseases [1] Group 1: Company Overview - Lingke Pharmaceutical is a leading developer of differentiated small molecule inhibitors targeting the JAK-STAT signaling pathway [1] - The company's key products include LNK01001, a second-generation JAK1 inhibitor, and LNK01004, a third-generation pan-JAK inhibitor, both aimed at autoimmune and inflammatory diseases [1] - LNK01006 is a high-selectivity TYK2 inhibitor that can penetrate the central nervous system, targeting related diseases [1] - The company has established an innovative proprietary IsoNova protein degradation platform to enhance target selectivity and reduce off-target effects [1] Group 2: Financial Performance - In 2023, 2024, and the first three quarters of 2025, the company reported revenues of approximately 20.57 million, 16.98 million, and 54.78 million yuan, respectively, with net losses of approximately -260 million, -312 million, and -145 million yuan [2] - The net loss in 2024 increased compared to 2023, primarily due to a surge in R&D expenses related to the advancement of LNK01001 into Phase III clinical trials [2] - As of September 30, 2025, the cumulative loss reached 1.1033 billion yuan [2] - The net cash flow from operating activities for the same periods was approximately -227.6 million, -240.9 million, and -85.7 million yuan [2] Group 3: Supply Chain and Dependency - The company relies heavily on the success of its clinical or preclinical candidates, having invested significant resources in the development of LNK01001 and LNK01004 [3] - The proportion of procurement from the top five suppliers increased from 53.2% in 2023 to 68.5% in 2025, indicating rising supply chain concentration [2] - This concentration may weaken bargaining power and could impact clinical progress if core suppliers face capacity constraints or terminate cooperation [2]

Core Viewpoint - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative small molecule inhibitors for autoimmune and inflammatory diseases, with a strong emphasis on the JAK-STAT signaling pathway [1] Group 1: Company Overview - Lingke Pharmaceutical is a leading developer of differentiated small molecule inhibitors targeting autoimmune and inflammatory diseases [1] - The company's clinical pipeline includes key products such as LNK01001, a selective second-generation JAK1 inhibitor, and LNK01004, a potential first-in-class third-generation pan-JAK inhibitor [1] - LNK01006 is a cutting-edge, highly selective TYK2 inhibitor that can penetrate the central nervous system, targeting related diseases [1] - The company has established an innovative proprietary IsoNova protein degradation platform to enhance target selectivity and reduce off-target effects [1] Group 2: Financial Performance - In the first three quarters of 2023, 2024, and 2025, the company reported revenues of approximately 20.573 million, 16.978 million, and 54.78 million respectively, with net losses of about 260 million, 312 million, and 145 million [2] - The net loss in 2024 is expected to widen compared to 2023, primarily due to increased R&D expenses from advancing LNK01001 into Phase III clinical trials [2] - As of September 30, 2025, the cumulative loss reached 1.1033 billion [2] - The net cash flow from operating activities for the first three quarters of 2023, 2024, and 2025 was approximately -227.6 million, -240.9 million, and -85.7 million respectively [2] Group 3: Supply Chain and Dependency - The proportion of procurement from the top five suppliers increased from 53.2% in 2023 to 68.5% in 2025, indicating a rising concentration in the supply chain [2] - This increasing concentration may weaken bargaining power and could directly impact clinical progress if core suppliers face capacity constraints or terminate cooperation [2] Group 4: Drug Development Risks - The company's future business and financial outlook heavily depend on the successful development of its candidate drugs, particularly LNK01001 and LNK01004 [3] - The success of these candidate drugs relies on multiple factors, many of which are beyond the company's control, including favorable safety and efficacy data, timely patient recruitment, and reliable performance from third-party service providers [3] - Even with regulatory approval, candidate drugs may lose competitiveness due to changes in clinical preferences, evolving industry standards, or innovations from competitors [3]

Company Overview - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - The company is a leading developer of innovative differentiated small molecule inhibitors targeting autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3] Product Pipeline - Key products include LNK01001, a highly selective second-generation JAK1 inhibitor, and LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor, both targeting autoimmune and inflammatory diseases [3] - LNK01006 is a cutting-edge, highly selective allosteric TYK2 inhibitor designed to penetrate the central nervous system, targeting related diseases [3] - The company has developed the proprietary IsoNova protein degradation platform, which enhances target selectivity and reduces off-target effects, expanding the range of degradable targets [3][4] Market Potential - The global JAK inhibitor market is projected to grow from $5.5 billion in 2019 to $13.9 billion in 2024, with expectations to reach $25.6 billion by 2028 and $40.8 billion by 2033 [6][16] - In China, the JAK inhibitor market is expected to expand from RMB 400 million in 2019 to RMB 3.8 billion in 2024, with forecasts of RMB 17.1 billion by 2028 and RMB 46.5 billion by 2033 [6][16] Clinical Development - As of the last feasible date, the company has 53 issued patents and 106 pending patent applications, with 34 issued patents and 45 pending applications related to its core and key products [7] - LNK01001 is currently undergoing multiple Phase III clinical trials, with new drug application stages expected in 2026 and 2027 for various indications [7] - LNK01004 has completed Phase II trials in China and plans to initiate Phase III trials in mid-2027 [7] Financial Performance - The company reported other income of RMB 20.57 million in 2023, RMB 16.98 million in 2024, and RMB 54.78 million for the nine months ending September 30, 2025 [9] - Annual losses were approximately RMB 260 million in 2023, RMB 312 million in 2024, and RMB 145 million for the nine months ending September 30, 2025 [10] - Research and development expenses were RMB 186 million in 2023, RMB 223 million in 2024, and RMB 121 million for the nine months ending September 30, 2025 [11] Industry Overview - The global market for autoimmune and inflammatory disease drugs grew from $133 billion in 2019 to $160.8 billion in 2024, with a compound annual growth rate (CAGR) of 3.9% [13] - The Chinese market for autoimmune and inflammatory disease drugs is expected to grow from RMB 42.7 billion in 2019 to RMB 66.5 billion in 2024, with a CAGR of 9.3% [13][14]

Core Viewpoint - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, aiming for a main board listing, with CITIC Securities (Hong Kong) Co., Ltd. and Jianyin International Financial Limited as joint sponsors [1] Company Overview - The company is a leading developer of innovative differentiated small molecule inhibitors for autoimmune and inflammatory diseases [1] - The clinical pipeline primarily focuses on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway [1] Key Products - The core products include LNK01001, a highly selective second-generation JAK1 inhibitor with potential to become a best-in-class treatment [1] - LNK01004 is a potential first-in-class third-generation soft pan-JAK inhibitor targeting autoimmune and inflammatory diseases [1] - LNK01006 is an advanced, highly selective allosteric TYK2 inhibitor that can penetrate the central nervous system, targeting diseases related to the central nervous system [1] Innovation Platform - The company has established an innovative proprietary IsoNova protein degradation platform, utilizing robust single-molecule design to eliminate inactive isomers, thereby providing clearer and superior safety profiles [1]

Company Overview - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - The company is a leading developer of innovative small molecule inhibitors for autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3] Product Pipeline - The core products include LNK01001, a highly selective second-generation JAK1 inhibitor; LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor; and LNK01006, a cutting-edge TYK2 inhibitor targeting central nervous system diseases [3][4] - The company has developed an innovative proprietary IsoNova protein degradation platform, enhancing target selectivity and reducing off-target effects, with potential applications beyond autoimmune diseases to oncology and neurodegenerative diseases [4] Market Potential - The global JAK inhibitor market is projected to grow from $5.5 billion in 2019 to $13.9 billion by 2024, with expectations to reach $25.6 billion by 2028 and $40.8 billion by 2033 [6][16] - In China, the JAK inhibitor market is expected to expand from RMB 400 million in 2019 to RMB 3.8 billion by 2024, with forecasts of RMB 17.1 billion by 2028 and RMB 46.5 billion by 2033 [6][16] Clinical Development - As of the last feasible date, the company has advanced its core candidates LNK01001 and LNK01004 into clinical stages, with LNK01001 undergoing multiple Phase III trials and LNK01004 having completed Phase II trials in China [7][8] - The company aims to maximize patient efficacy and safety through the development of innovative candidates, with several preclinical candidates also in the pipeline [8] Financial Performance - The company reported other income of RMB 20.57 million, RMB 16.98 million, and RMB 54.78 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual losses for the same periods were approximately RMB 260 million, RMB 312 million, and RMB 145 million [10] - Research and development expenditures were approximately RMB 186 million, RMB 223 million, and RMB 121 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [11] Industry Overview - The global market for autoimmune and inflammatory disease drugs has grown from $133 billion in 2019 to $160.8 billion in 2024, with a projected CAGR of 3.9% [12] - The Chinese market for autoimmune and inflammatory disease drugs is expected to grow from RMB 42.7 billion in 2019 to RMB 66.5 billion by 2024, with a CAGR of 9.3% [13][14]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引 致的任何損失承擔任何責任。 LYNK PHARMACEUTICALS CO., LTD. 凌科藥業（浙江）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 警 告 (a) 本文件僅向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中的 資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司、本公司的聯席保薦 人、整體協調人、顧問或包銷團成員在香港或任何其他司法權區必須進行發售活動的責任。本公司 最終會否進行任何發售仍屬未知之數； (c) 本文件或其任何補充、修訂或更換附頁的內容可能會亦可能不會在最後正式的上市文件內全部或部 分轉載； (d) 本文件並非最終的上市文件，本公司可能不時根據聯交所證券上市規則作出更新或修訂； (e) 本文件並不構成向任何司法權區的公眾人士提呈出售任何證券的招股章程、發售通函、通知、通 告、小冊子或廣告，亦非邀請公眾提出認購 ...